Cancer

Title
PCI-32765MCL3002 (Ibrutinib) vs Placebo in Combination with Bendamustine and Rituximab in Frontline Mantle Cell Lymphoma Patients.
Trial Number
205182051513
Number of Participants
520
Principal Investigator

Patrick Stiff

M.D.
Hematology/Oncology
Coleman Professor of Oncology
Eligibility

Participants must be age 65 or older with treatment niave, newly diagnosed mantle cell lymphoma with no prior treatment; Participants must have bi-dimensional measurable disease and an ECOG performance status 0 or 1.

Purpose

The purpose of this study is to compare the effects (bad and good) of ibrutinib when it is given with a chemotherapy regimen of bendamustine and rituximab to bendamustine and rituximab alone in people with newly diagnosed mantle cell lymphoma.

Enrollment

(708) 327-3228

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.